Testing an imaging agent to help doctors spot glioma in people with brain tumors
Original title: Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early first test in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether a special scan can give doctors a clearer look at a brain tumor.
Who this trial is for. This trial is for people who have a brain tumor. It is testing an imaging agent called hyperpolarized carbon C 13 pyruvate. The agent is given before a scan called magnetic resonance spectroscopic imaging, or MRSI.
Where it stands. The trial is looking at how well this agent helps doctors diagnose glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary. The trial has not reported results. There is no answer yet.
What this means, and what it doesn't
What it could mean: If it works, it could give doctors a clearer way to tell what kind of brain tumor a person has. Someone who fits this study could ask their care team about it.
What it doesn't mean: This does not mean the scan is proven. A trial is a test, not a proven treatment. Taking part is not a promise of any benefit. This is not a cure. It is a way of looking at a tumor, not a way of treating one.
Source: ClinicalTrials.gov, July 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.